San Antonio Center Cleared to Commence Commercial Sales of Normal Source PlasmaState of the Art Facility has Annual Collection Capacity of Approximately 50,000 Liters of Plasma and an Estimated Annual Revenue Contribution of $8 Million to $10 Million at its Full CapacityThe Center is Structured to Collect Normal Source Plasma and Specialty Plasma, such as Anti-Rabies and Anti-D; Anticipated to be One of the Largest Centers for Specialty Plasma Collection in the U.S. REHOVOT, Israel and HOBOKEN, N.J., March ...

分组1 - Kamada Ltd. reported a 4Q25 GAAP EPS of $0.06, missing consensus estimates by approximately $0.02 [1] - Revenue for the quarter was $44.68 million, reflecting a year-over-year growth of 14.6%, but fell short of estimates by about $1.94 million [1] 分组2 - The company has a focus on biotechnology, particularly in identifying innovative companies with unique mechanisms of action and first-in-class therapies [1] - The analysis emphasizes the importance of evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities [1]

Group 1 - Kamada Ltd. is a global biopharmaceutical company focused on developing treatments for rare and serious conditions, operating in the Zacks Medical - Biomedical and Genetics industry [1] - Stifel Nicolaus has set a price target of $11 for Kamada, indicating a potential upside of 28.73% from its current price of $8.54 [1][6] - Kamada reported a fourth-quarter profit of $0.06 per share, which was below the Zacks Consensus Estimate of $0.09 per share, marking a 30.8% negative surprise [2][6] Group 2 - The company generated $44.68 million in revenue for the quarter ending December 2025, which was 2.29% below the Zacks Consensus Estimate but an improvement from $39.01 million in the same period the previous year [3] - For the full year 2025, Kamada achieved a record revenue of $180.5 million, marking a 12% increase compared to the previous year, with adjusted EBITDA rising by 23% to $42 million and net income surging by 40% to $20.2 million [3] - Looking forward, Kamada projects revenues between $200 million and $205 million for 2026, alongside an adjusted EBITDA ranging from $50 million to $53 million, indicating continued double-digit organic growth [4][6] Group 3 - Kamada's stock is currently trading at $8.54, reflecting a decrease of 4.69% or $0.42, with a market capitalization of approximately $492.6 million [5] - The stock has traded between a low of $8.41 and a high of $8.70 today, and over the past year, it has reached a high of $9.35 and a low of $5.54 [5]

Core Viewpoint - Kamada reported strong operational and financial performance in 2025, with positive momentum heading into 2026, despite potential logistical challenges due to the situation in the Middle East [1]. Operations Update and 2025 Results - The manufacturing plant has been operating continuously, with operations and product manufacturing proceeding as planned. Although exports from Israel may face temporary impacts due to airspace closures, cargo flights have resumed, and no material disruption to product supply is anticipated [2]. - For the full year 2025, total revenues reached $180.5 million, reflecting a 12% year-over-year increase, while adjusted EBITDA was $42 million, up 23%. The company generated $25.5 million in cash from operating activities, resulting in a year-end cash position of $75.5 million [2]. Revenue Growth Drivers - Revenue growth in 2025 was attributed to increased sales across the portfolio, particularly for Varizig and KedRAB in the U.S., KAMRAB and GLASSIA in international markets, and higher distribution segment sales supported by biosimilar launches and other products [3]. Dividend Declaration and 2026 Outlook - Based on the strong 2025 results, the board declared a dividend of $0.25 per share, totaling approximately $14.4 million, payable on April 6 to shareholders of record as of March 23. This aligns with the company's policy to distribute at least 50% of annual net income as dividends [4]. - The company affirmed its 2026 guidance, projecting revenues of $200 million to $205 million and adjusted EBITDA of $50 million to $53 million, representing growth of 13% and 23% respectively compared to 2025 results. The outlook is based solely on organic growth, with any business development or M&A activities considered incremental [5]. Product and Commercial Highlights - KedRAB, the company's lead product, saw sales to Kedrion Biopharma increase to approximately $54 million in 2025, exceeding the contract minimum commitment. Kamada has a firm commitment of $90 million from Kedrion for minimum orders from 2026 through 2027, with the current supply agreement extending through 2031 [6].

Financial Data and Key Metrics Changes - Total revenues for 2025 were $180.5 million, representing a 12% year-over-year increase from $161 million in 2024 [5][17] - Adjusted EBITDA was $42 million, up 23% year-over-year from $34.1 million in 2024 [5][19] - Net income for 2025 was $20.2 million or $0.35 per diluted share, a 40% increase compared to $14.5 million or $0.25 per diluted share in 2024 [19] - Cash and cash equivalents at year-end 2025 were $75.5 million, down from $78.4 million in December 2024 [19] Business Line Data and Key Metrics Changes - Sales of KedRAB increased to approximately $54 million in 2025, exceeding the contract minimum commitment [10] - GLASSIA contributed total revenue of $35 million, with growth in both ex-U.S. markets and royalty income from Takeda [10] - Revenues from Cytogam declined due to increased usage of antivirals, with ongoing efforts to demonstrate its advantages through a new clinical study [11][12] Market Data and Key Metrics Changes - The company secured a $10 million-$14 million extension of an existing tender from Canadian Blood Services for various products, ensuring ongoing sales in Canada from Q2 2026 to Q1 2028 [17] - The distribution segment is expected to grow through the launch of additional biosimilars in Israel and expansion into the MENA region [9][14] Company Strategy and Development Direction - The company focuses on expanding its commercial product portfolio, including investment in FDA-approved specialty plasma-derived products and biosimilars [9] - Plans to ramp up plasma collection at new centers in Houston and San Antonio, with expected annual revenues of $8 million-$10 million at full capacity [15] - The company aims to secure new business development and M&A transactions to enhance its product portfolio and generate synergies [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to meet supply obligations despite geopolitical challenges in the Middle East [4] - The company affirmed its 2026 annual guidance of $200 million-$205 million in revenues and $50 million-$53 million in adjusted EBITDA, representing 13% and 23% growth, respectively [8] - Management emphasized the importance of Cytogam as additional protection for high-risk organ transplant recipients and the potential for increased usage following clinical studies [25] Other Important Information - A dividend of $0.25 per share, totaling approximately $14.4 million, was declared, reinforcing confidence in business prospects and liquidity for growth investments [6][7] Q&A Session Summary Question: CMV market and Cytogam usage - Management noted no changes in CMV management protocols but acknowledged increased access to antivirals affecting Cytogam usage [23][24] Question: M&A opportunities and dividend implications - Management confirmed that the dividend payment does not indicate a change in M&A opportunities, expressing optimism for securing transactions in 2026 [26] Question: Plasma collection growth margin benefits - Management expects growth margin benefits from proprietary plasma collection to start impacting gross profit in 2027 and beyond [27] Question: Plasma collection center ramp-up - Current ramp-up is at 30%-40%, with full capacity expected by the end of 2027 [31] Question: Timing for new biosimilars - New biosimilars are expected to launch around mid-2026, with sales ramping up based on market demand [32] Question: Dividend payment timing - The entire dividend will be paid out in the second quarter [40]

Financial Data and Key Metrics Changes - Total revenues for 2025 were $180.5 million, representing a 12% year-over-year increase from $161 million in 2024 [5][17] - Adjusted EBITDA was $42 million, up 23% year-over-year from $34.1 million in 2024 [5][19] - Net income for 2025 was $20.2 million or $0.35 per diluted share, a 40% increase compared to $14.5 million or $0.25 per diluted share in 2024 [19] - Cash and cash equivalents at year-end 2025 were $75.5 million, down from $78.4 million in December 2024 [19] Business Line Data and Key Metrics Changes - Sales of KedRAB increased to approximately $54 million in 2025, exceeding the contract minimum commitment [10] - GLASSIA contributed total revenue of $35 million, with growth in both ex-U.S. markets and royalty income from Takeda [10] - Revenues from Cytogam declined due to increased usage of antivirals, with ongoing efforts to demonstrate its advantages through a new clinical study [11][12] Market Data and Key Metrics Changes - The company secured a $10 million-$14 million extension of an existing tender from Canadian Blood Services for various products, ensuring ongoing sales in Canada from Q2 2026 to Q1 2028 [17] - The company anticipates growth in its distribution segment through the launch of additional biosimilars in Israeli markets and expansion into the MENA region [9][14] Company Strategy and Development Direction - The company focuses on expanding its commercial product portfolio, including investment in FDA-approved specialty plasma-derived products and biosimilars [9] - Plans to ramp up plasma collection at new centers in Houston and San Antonio, with expected annual revenues of $8 million-$10 million per center at full capacity [15] - The company is pursuing new business development and M&A opportunities to enhance its product portfolio and generate synergies [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's operational and financial performance, despite geopolitical challenges in the Middle East [4] - The company affirmed its 2026 annual guidance of $200 million-$205 million in revenues and $50 million-$53 million in adjusted EBITDA, representing growth from 2025 results [8] - Management emphasized the importance of Cytogam in organ transplant protection and the potential for increased usage following clinical studies [25] Other Important Information - A dividend of $0.25 per share was declared, totaling approximately $14.4 million, reinforcing confidence in business prospects [6][7] - The company plans to continue investing in growth while maintaining dividend payments [26] Q&A Session Summary Question: CMV market and Cytogam usage - Management noted no changes in CMV management protocols but acknowledged increased access to antivirals affecting Cytogam usage [23][24] Question: M&A opportunities and dividend implications - Management confirmed that the dividend payment does not indicate a change in M&A opportunities, expressing optimism for securing transactions in 2026 [26] Question: Plasma collection growth margin benefits - Management expects growth margin benefits from plasma collection to start impacting gross profit in 2027 and beyond [27] Question: Plasma collection center ramp-up - Current ramp-up is at 30%-40%, with full capacity expected by the end of 2027 [31] Question: Timing for new biosimilars launch - New biosimilars are expected to launch around mid-2026, with sales ramping up based on market demand [32] Question: Dividend payment timing - The entire dividend will be paid in the second quarter [39]

Financial Data and Key Metrics Changes - Total revenues for 2025 were $180.5 million, a 12% year-over-year increase from $161 million in 2024 [5][17] - Adjusted EBITDA for 2025 was $42 million, reflecting a 23% increase compared to $34.1 million in 2024 [5][19] - Net income for 2025 was $20.2 million, or $0.35 per diluted share, a 40% increase from $14.5 million, or $0.25 per diluted share, in 2024 [19] - Cash and cash equivalents at year-end 2025 were $75.5 million, down from $78.4 million in December 2024 [19] Business Line Data and Key Metrics Changes - Sales of KedRAB increased to approximately $54 million in 2025, exceeding the contract minimum commitment [10] - GLASSIA contributed total revenue of $35 million, with growth in ex-U.S. markets and royalty income from Takeda [10] - Revenue from Cytogam declined due to increased usage of antivirals, but a comprehensive post-marketing research program is expected to support future growth [11][12] Market Data and Key Metrics Changes - The company anticipates growth in the distribution segment through the launch of additional biosimilars in Israeli markets and expansion into the MENA region [9][13] - The Canadian Blood Services awarded a $10 million-$14 million extension for the supply of various products, securing ongoing sales in the Canadian market [17] Company Strategy and Development Direction - The company focuses on expanding its commercial product portfolio and investing in the commercialization of FDA-approved specialty plasma-derived products [9] - Plans to ramp up plasma collection at new centers, aiming for significant revenue generation from normal source plasma sales starting in 2026 [14] - The company is pursuing M&A opportunities to enrich its product portfolio and generate synergies with existing operations [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's operational and financial performance, despite geopolitical challenges in the Middle East [4] - The company affirmed its 2026 guidance of $200 million-$205 million in revenues and $50 million-$53 million in adjusted EBITDA, representing growth from 2025 results [7][8] - Management emphasized the importance of Cytogam in organ transplant protection and the potential for increased utilization following ongoing clinical studies [24] Other Important Information - A dividend of $0.25 per share, totaling approximately $14.4 million, was declared, reinforcing confidence in business prospects and liquidity [6] - The company expects to launch two additional biosimilars in Israel in mid-2026, contributing to growth in the distribution business [13][32] Q&A Session Summary Question: Impact of antivirals on Cytogam market - Management noted no change in CMV management protocols but acknowledged increased access to antivirals affecting Cytogam usage [22][23] Question: M&A opportunities and dividend implications - Management confirmed that the dividend payment does not indicate a change in M&A opportunities, expressing optimism for securing transactions in 2026 [25] Question: Plasma collection growth margin benefits - Management expects growth margin benefits from proprietary plasma collection to start impacting gross profit in 2027 and beyond [26] Question: Ramp-up of plasma collection centers - Current ramp-up is at 30%-40%, with full capacity expected by the end of 2027 [31] Question: Timing of biosimilars launch - Two additional biosimilars are expected to launch around mid-2026, with sales ramping up based on market demand [32] Question: Dividend payment schedule - The entire dividend will be paid in the second quarter [40]

Financial Projections - The company expects total revenues for fiscal year 2026 to be in the range of $200 million to $205 million, representing a year-over-year increase of 13%[22]. - Adjusted EBITDA for fiscal year 2026 is projected to be between $50 million and $53 million, indicating a 23% increase year-over-year[22]. - The company plans to pay a cash dividend of $0.25 per share on April 6, 2026, totaling approximately $14.4 million[22]. - The company anticipates receiving royalties from Takeda in the range of $10 million to $20 million per year from 2026 to 2040 based on current GLASSIA sales[22]. - The company expects to launch two biosimilar products in Israel in 2026, with an estimated revenue increase from existing biosimilar products to between $15 million and $20 million within the next four to five years[23]. - The company projects that its plasma collection centers in Houston and San Antonio will generate annual revenues of approximately $8 million to $10 million once fully operational[23]. - The company expects Kedrion Biopharma Inc. to purchase minimum quantities of KEDRAB, generating approximately $180 million in revenue during the first four-year period of the amended agreement[23]. Operational Plans - The company plans to transition the manufacturing of HEPAGAM B, VARIZIG, and WINRHO SDF to its facility in Beit Kama, Israel, within four to five years[22]. - The company intends to invest in ramping up U.S. plasma collection operations, with expectations for FDA approval of the San Antonio site in the first half of 2026[23]. - The company has invested in ramping up U.S. plasma collection operations, with three centers currently operational, aiming to reduce dependency on third-party suppliers and generate sales from normal source plasma[45]. - The company is expanding its plasma collection operations to support the sale of normal source plasma to third-party manufacturers, which exposes it to risks related to customer concentration and pricing volatility[92]. - The company currently operates three plasma collection centers in the United States, with the first center acquired in March 2021 and the second center opened in 2024, while the third center is expected to receive FDA approval in the first half of 2026[87]. Revenue Sources - The company relies heavily on sales from its three leading products: KEDRAB, GLASSIA, and CYTOGAM, which accounted for approximately 59% of total revenues for the year ended December 31, 2025[38]. - Revenue from Proprietary Products comprised approximately 87%, 88%, and 81% of total revenues for the years ended December 31, 2025, 2024, and 2023, respectively[41]. - Kedrion accounted for approximately 30%, 31%, and 23% of total revenues in 2025, 2024, and 2023, respectively, with projected minimum aggregate revenues of approximately $180 million over the four-year period from 2024 to 2027[48]. - Sales of CYTOGAM, VARIZIG, HEPAGAM B, and WINRHO SDF represented approximately 19%, 24%, and 21% of Proprietary Product segment sales for the years ended December 31, 2025, 2024, and 2023, respectively[51]. - Sales through third-party distributors accounted for approximately 28%, 22%, and 26% of total revenues in 2025, 2024, and 2023, respectively, with expectations for an increase in 2026 and beyond[56]. Market and Competitive Landscape - The company believes that the market opportunity for AAT products will continue to grow as awareness of Alpha-1 Antitrypsin Deficiency increases[24]. - The company faces competition from large biopharmaceutical companies, which may have advantages in financial resources and market presence[60]. - The company faces competition in the hyper-immune IgG products segment from Grifols and CSL Behring, both of which operate over 300 plasma collection centers in the U.S.[62]. - Competitors are conducting clinical trials for gene therapies and recombinant AAT, which could adversely affect the company's revenue and GLASSIA sales if successful[63]. - Sanofi's acquisition of INBRX-101, a treatment for AATD, may intensify competition and impact demand for plasma-derived AAT products[63]. Regulatory and Compliance Risks - The company faces risks related to maintaining relationships with third-party distributors and suppliers, which are critical for the availability of its products[37]. - Future growth is dependent on the successful expansion of U.S. commercial and distribution infrastructure, as well as international commercialization efforts[37]. - The manufacturing facility's capacity and regulatory approvals are crucial for the production of new plasma-derived products, which may not materialize as planned[43]. - Regulatory compliance issues in plasma collection and fractionation processes could lead to inventory impairments and adversely affect financial results[79][80]. - The company must comply with government pricing programs, and failure to do so could result in penalties and affect participation in government healthcare programs[184]. Financial Health and Risks - The company has incurred significant losses since inception and may continue to do so in the future, despite being profitable in recent years[39]. - The company reported an accumulated deficit of $17.1 million as of December 31, 2025, despite being profitable in the years ended December 31, 2025, 2024, and 2023[216]. - The company may face challenges in attracting donors to its plasma collection centers, which could hinder its ability to meet production targets[91]. - The company may face increased costs and delays in production due to evolving cGMP standards and the need for new testing methods[72]. - The company may face significant competition in the Distribution segment from larger companies, which may affect market share and profitability[120]. Intellectual Property and Legal Risks - The company’s patents are set to expire between 2027 and 2044, which may limit competitive advantages during commercialization[202]. - The company may face claims of infringing third-party intellectual property rights, which could result in significant legal expenses and operational disruptions[209]. - The company may rely on licensors for patent prosecution and maintenance, which could adversely affect its rights to therapeutic candidates and marketed products[198]. - The company faces risks related to unauthorized use of its intellectual property, which could adversely affect business and reduce product demand[203]. - The company has entered into license agreements that impose obligations, including maintaining patents and making milestone payments, which if not met could lead to loss of rights[210].

Core Viewpoint - Kamada Ltd. reported strong financial performance for 2025, achieving record revenues and adjusted EBITDA, and is optimistic about continued growth in 2026 with affirmed guidance [2][5][10]. Financial Performance - Total revenues for 2025 were $180.5 million, a 12% increase from $161.0 million in 2024 [6]. - Adjusted EBITDA for 2025 was $42.0 million, reflecting a 23% increase from $34.1 million in 2024 [5][13]. - Net income for 2025 was $20.2 million, a 40% increase compared to $14.5 million in 2024 [5][6]. - The company generated $25.5 million in cash from operating activities in 2025, contributing to a cash position of $75.5 million at year-end [2][5]. 2026 Guidance - Kamada affirmed its 2026 annual guidance, projecting revenues between $200 million and $205 million, and adjusted EBITDA between $50 million and $53 million, representing year-over-year growth of 13% and 23% respectively [2][10][19]. Strategic Focus - The company plans to expand its commercial product portfolio, invest in the commercialization of FDA-approved specialty plasma-derived products, and grow its Distribution segment through new biosimilar products [3][19]. - Kamada aims to enhance plasma collection operations to support revenue growth and reduce costs [3][19]. - The company is also looking to secure new business development and M&A transactions to accelerate profitable growth and enrich its product portfolio [5][19]. Dividend Policy - Kamada adopted an annual cash dividend policy, declaring a cash dividend of $0.25 per share, totaling approximately $14.4 million, to be paid on April 6, 2026 [5][14]. Recent Developments - The company announced a $10 million to $14 million extension of an existing tender with Canadian Blood Services for the supply of specialty plasma-derived products [14]. - Kamada discontinued its Phase 3 Inhaled AAT clinical trial [14].

Core Viewpoint - Kamada Ltd. reported record revenue and profitability for the full year 2025 and declared a cash dividend of $0.25 per share, totaling approximately $14.4 million, to be paid on April 6, 2026 [1][2][3] Financial Performance - The company announced strong financial results for 2025, which supported the decision to distribute a cash dividend [3] - The cash dividend represents at least 50% of the company's annual net income, as per the newly adopted annual cash dividend policy [2] Dividend Policy - The Board of Directors has adopted a policy to distribute an annual dividend of at least 50% of net income, subject to discretion and legal requirements [2] - The dividend payment will be subject to tax withholding in accordance with Israeli tax law [3] Company Overview - Kamada Ltd. is a global biopharmaceutical company focused on rare and serious conditions, with a portfolio of specialty plasma-derived products [4] - The company is controlled by FIMI Opportunity Funds, which owns approximately 38% of the outstanding shares [4] Growth Strategy - Kamada's growth strategy includes organic growth of its commercial portfolio, distribution of third-party pharmaceutical products, ramping up plasma collection operations, and pursuing mergers and acquisitions [4] - The company aims to enhance its marketed products portfolio and leverage its financial strength for long-term growth [4]